BWM
RPRX icon

BerganKDV Wealth Management’s Royalty Pharma RPRX Stock Holding History

BerganKDV Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14
Closed -$505 – 1038
2023
Q1 		$505 Buy
+14
New +$519 ﹤0.01% 972

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BerganKDV Wealth Management's RPRX Position: Q2 2023 in Review

BerganKDV Wealth Management sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 14 shares — an estimated $505 sold.

BerganKDV Wealth Management first reported a position in RPRX in Q1 2023 and held it in 1 quarter. The position peaked at $505 in Q1 2023. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

  • BerganKDV Wealth Management reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
  • BerganKDV Wealth Management sold 14 Royalty Pharma shares in Q2 2023, an estimated $505.
  • BerganKDV Wealth Management first reported a position in Royalty Pharma in Q1 2023 and held it in 1 quarter.
  • BerganKDV Wealth Management's Royalty Pharma position peaked at $505 in Q1 2023.
  • 325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on BerganKDV Wealth Management's 13F filing for Q2 2023, filed 24 Jul 2023.